This Dividend King truly wears the crown.Certifications such as the Good Housekeeping Seal help consumers know which products are safe and perform well. Unfortunately, no Good Housekeeping Seal exists for dividend stocks.However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a company must increase its dividend for at least 50 consecutive years. Most income investors will sleep better at night knowing that a stock has such an impressive divid ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about AbbVie (ABBV) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.AbbVie currently has an average brokerage recommendation (ABR) of ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.If you're investing in stocks that have long track records for increasing their payouts, odds are, you're buying shares of them because of their stability and the potential for dividend income. But just because a stock is an excellent dividend investment doesn't mean it can't also be a top growth stock to own. Stocks that can balance both dividends and growth can give investors the best of b ...

Everybody loves dividends, as they provide a passive income stream, limit drawdowns in other positions, and provide more than one way to profit from an investment.And when considering dividend-paying stocks, those with a history of boosting their payout are prime considerations, reflecting their commitment to increasingly rewarding shareholders.In addition, consistent dividend hikes reflect the company’s successful nature, opting to share profits with shareholders.And recently, three companies – AbbVie (ABB ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this drugmaker have returned +3.5% over the past month versus the Zacks S&P 500 composite's -0.5% change. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 4.8% over this period. Now the key question is: Where could the stock be headed in the near term?While media releases or rumors ab ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35565 AbbVie Inc. (Exact name of registrant as specified in its charter) Delaware 32-0375147 (State or other jurisdiction o ...

Core Insights - AbbVie has successfully navigated the challenges of losing patent protection for Humira, maintaining growth through its strong immunology portfolio and diversification efforts [1][2] - Despite a significant decline in Humira sales, AbbVie has seen substantial increases in sales from Rinvoq and Skyrizi, which are expected to continue to grow [2][3] Financial Performance - AbbVie reported Q3 sales of $14.46 billion, reflecting a 3.8% year-over-year increase, surpassing consensus estimates by 120 basis points [2][3] - The immunology segment grew by 4.8%, driven by a 13% increase in oncology sales and a 15.6% increase in neuroscience sales [2][3] - Adjusted earnings reached $3.00, up 1.7% year-over-year, exceeding forecasts by 270 basis points, indicating strong financial health [3] Guidance and Analyst Reactions - AbbVie raised its adjusted diluted EPS guidance, indicating strong operational momentum and expectations for continued growth in 2025 [4][5] - Analysts have responded positively to AbbVie's Q3 results, with all tracked revisions indicating higher price targets, suggesting a bullish outlook for the stock [5][6] Market Performance - Following the Q3 release, AbbVie’s stock price increased by 7%, reaching a new all-time high, supported by strong trading volume [7] - Technical indicators suggest a continued uptrend, with price targets ranging from $212 to $220 aligning with analyst revisions [7] Dividend and Capital Return - AbbVie offers a solid dividend yield of over 3.2%, which is significantly higher than the broad market average, indicating strong capital return potential [6]

Core Insights - AbbVie and EvolveImmune Therapeutics have announced a collaboration to develop multispecific therapeutic antibodies for cancer treatment, leveraging EvolveImmune's proprietary T-cell engager platform [1][3] - The partnership aims to address therapeutic challenges in both solid and hematologic malignancies by enhancing T-cell functionality and overcoming cancer cell resistance [2][3] Financial Terms - EvolveImmune will receive $65 million in upfront fees and equity investment from AbbVie, with potential for up to $1.4 billion in option fees and milestones, along with tiered royalty payments on net sales [3] Company Profiles - AbbVie is focused on advancing cancer treatment through innovative therapies and has a dynamic pipeline targeting various cancer types, including blood cancers and solid tumors [5][6] - EvolveImmune is developing first-in-category biotherapeutics aimed at overcoming cancer-driven immunodeficiency, with first-in-human clinical trials expected in 2025 [7]

Core Insights - Dividend-paying stocks have significantly outperformed non-payers, making them a powerful long-term investment option [1][2] Performance Data - From 1973 to 2023, the average annual total return for different categories of dividend stocks is as follows: - Dividend growers and initiators: 10.19% - Dividend payers: 9.17% - No change in dividend policy: 6.74% - Dividend non-payers: 4.27% - Dividend shrinkers and eliminators: (0.63%) - Equal-weighted S&P 500 index: 7.72% [3] Recommended Dividend Stocks - Five promising dividend-paying stocks include: 1. **Altria (MO)**: Yield 8.2%, 5-Year Avg. Dividend Growth Rate 4%, 10-Year Avg. Annual Return 5.51% [5][6] 2. **Chevron (CVX)**: Yield 4.3%, 5-Year Avg. Dividend Growth Rate 6.5%, 10-Year Avg. Annual Return 5.65% [5][8] 3. **Verizon Communications (VZ)**: Yield 6.5%, 5-Year Avg. Dividend Growth Rate 2%, 10-Year Avg. Annual Return 3.12% [5][9] 4. **AbbVie (ABBV)**: Yield 3.3%, 5-Year Avg. Dividend Growth Rate 7.7%, 10-Year Avg. Annual Return 14.45% [5][10] 5. **Realty Income (O)**: Yield 5%, 5-Year Avg. Dividend Growth Rate 3.7%, 10-Year Avg. Annual Return 7.4% [5][11] ETF Options - For those less confident in selecting individual stocks, several dividend-focused ETFs are available: - SPDR Portfolio S&P 500 High Dividend ETF (SPYD): Yield 4.18%, 5-Year Avg. Annual Return 8.67% [14] - Schwab U.S. Dividend Equity ETF (SCHD): Yield 3.61%, 5-Year Avg. Annual Return 13.05% [14] - iShares Core Dividend Growth ETF (DGRO): Yield 2.24%, 5-Year Avg. Annual Return 12.59% [14] - Vanguard Dividend Appreciation ETF (VIG): Yield 1.65%, 5-Year Avg. Annual Return 12.93% [14]

Group 1 - AbbVie Inc. (NYSE: ABBV) has not seen significant movement in its share price since August, but the release of its Q3 2024 results indicates investor satisfaction [1] - The company is being analyzed by a macroeconomist with over 20 years of experience in various industries, including investment management and investment banking [1] Group 2 - The investing group Green Growth Giants focuses on opportunities in the green economy, building on the themes presented in the Long Term Tips profile [1]